Shares jumped +6.5% to $11.56 as Telix Pharmaceuticals announced it completed enrollment of 350 patients in its Phase 3 BiPASS study — a late-stage trial testing whether combining its PET scan imaging agents with MRI can better detect prostate cancer before a biopsy, potentially sparing men from unnecessary invasive procedures. Telix also aligned with the FDA on a New Drug Application pathway that, if approved, would support reimbursement as a new product and broaden patient access. For a company already generating nearly $1 billion in annual revenue, the news signals that Telix's prostate imaging business still has room to grow.

  • Enrollment Speed Shows Strong Physician Interest. By Q2 2026, Telix had rapidly enrolled 338 of the 350 patients , finishing the final dozen in just weeks. BiPASS is the first registrational study of PSMA-PET imaging in the pre-biopsy setting — meaning no competitor has completed a comparable trial. That first-mover data could lock in prescriber habits and set the reimbursement benchmark.

  • The FDA Pathway Opens a Much Bigger Patient Pool. Telix's imaging products are currently approved for men with known or suspected recurring prostate cancer. The FDA engagement supports "new product reimbursement" that would "broaden access to PSMA-PET imaging across a significantly larger patient population."

The U.S. performs roughly one million prostate biopsies each year — capturing even a fraction of the pre-biopsy screening market would materially lift Telix's imaging revenue, which already hit $202 million in Q2 alone, up 30% year-over-year.

  • Revenue Is Tracking, but R&D Costs Are Climbing. Telix expects FY 2026 revenue and other income to exceed US$1 billion, tracking the upper end of guidance of $950–$970 million plus $40 million from a Regeneron partnership. However, the company raised its R&D spending forecast to $230–$270 million , reflecting the cost of running multiple pivotal trials simultaneously. Investors should watch whether rising trial expenses compress margins before new approvals generate returns.

  • The Stock Reversed a Weeklong Slide — Sustainability Is the Question. TLX fell from $11.38 to $10.85 over four sessions before today's bounce. Telix's commercial franchise spans 22 countries and its therapeutic pipeline includes three assets in pivotal trials across prostate, brain, and kidney cancers. The BiPASS data readout, likely months away, becomes the next binary catalyst: positive results could justify a sustained move higher, while any miss would undercut the entire pre-biopsy expansion thesis.